Raghav Sundar

Sundar Raghav

  • Assistant Professor, Department of Medicine
  • Consultant, Department of Haematology-Oncology
Academic Qualifications
  • MCI, FAMS (Oncology)
  • MMed(Int Med)
  • MRCP(UK)
  • MBBS(S'pore)
Recent Publications
  • 1. Molassiotis, A., Cheng, H. L., Leung, K. T., Li, Y. C., Wong, K. H., Au, J. S. K., . . . Lopez, V. (2019). Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. BRAIN AND BEHAVIOR, 9(6), 10 pages. doi:10.1002/brb3.1312.
  • 2. Yeo, F., Ng, C. C., Loh, K. W. J., Molassiotis, A., Cheng, H. L., Au, J. S. K., . . . Chan, A. (2019). Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.. Support Care Cancer. doi:10.1007/s00520-019-04771-8.
  • 3. Garces, A. H. I., Ang, J. E., Ameratunga, M., Chenard-Poirier, M., Dolling, D., Diamantis, N., . . . Banerji, U. (2018). A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. EUROPEAN JOURNAL OF CANCER, 104, 32-38. doi:10.1016/j.ejca.2018.08.019.
  • 4. Basu, B., Krebs, M. G., Sundar, R., Wilson, R. H., Spicer, J., Jones, R., . . . Banerji, U. (2018). Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. ANNALS OF ONCOLOGY, 29(9), 1918-1925. doi:10.1093/annonc/mdy245.
  • 5. Yong, W. P., Rha, S. Y., Tan, I. B. -H., Choo, S. -P., Syn, N. L., Koh, V., . . . Tan, P. (2018). Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial. CLINICAL CANCER RESEARCH, 24(21), 5272-5281. doi:10.1158/1078-0432.CCR-18-0193.